Sanofi (SNY) Earnings Analysis
Sanofi (SNY) next reports earnings on 2026-07-30, consensus EPS 1.09 USD. Last quarter (2026-04-23) it beat with EPS 1.1 USD vs 1.06 USD est (+3.8%). It has beaten estimates in 6/8 recent quarters (75%). Trailing P/E 12.27.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does SNY next report earnings?
| Next earnings date | 2026-07-30 |
|---|---|
| Consensus EPS estimate | 1.09 USD |
| Revenue estimate | 12.44B |
SNY earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-04-23 | 1.1 USD | 1.06 USD | +3.8% | Beat |
| 2026-01-29 | 0.89 USD | 0.84 USD | +6% | Beat |
| 2025-10-24 | 1.7 USD | 1.6 USD | +6.2% | Beat |
| 2025-07-31 | 0.9 USD | 0.96 USD | -6.2% | Miss |
| 2025-04-24 | 0.94 USD | 0.9 USD | +4.4% | Beat |
| 2025-01-30 | 0.7 USD | 0.71 USD | -1.4% | Miss |
| 2024-10-25 | 1.57 USD | 1.35 USD | +16.3% | Beat |
| 2024-07-25 | 0.93 USD | 0.86 USD | +8.1% | Beat |
Beat rate: 6/8 (75%) over reported quarters with consensus data.
SNY valuation and analyst view
| Trailing P/E | 12.27 |
|---|---|
| Trailing EPS | 3.14 USD |
| Price / book | 1.26 |
| Dividend yield | 5.42% |
| Market cap | 105.49B |
| Analyst consensus | Hold (12 buy / 14 hold / 1 sell) |
| Avg price target | 50.5 USD |
Related research pages
Frequently asked questions
When is Sanofi (SNY)'s next earnings date?
Sanofi is next scheduled to report on 2026-07-30, with a consensus EPS estimate of 1.09 USD and revenue estimate of 12.44B.
Did SNY beat earnings last quarter?
In its 2026-04-23 report, SNY posted EPS of 1.1 USD versus a 1.06 USD estimate — a beat of 3.8%.
What is SNY's earnings track record?
Over the last 8 reported quarters with consensus data, SNY beat estimates 6 times (75%).
What is SNY's current P/E ratio and EPS?
SNY trades at a trailing P/E of 12.27 on trailing EPS of 3.14 USD.
What do analysts rate SNY?
Analyst consensus is "Hold" across 27 ratings (0 strong buy, 12 buy, 14 hold, 1 sell, 0 strong sell). Average 12-month price target: 50.5 USD.